Skip to main content
AMCP Nexus 2024 Main banner
Back

Managed Care Research in Action

GLP-1 Agonists for Weight Management within the Commercially Insured Market: How Real-world Evidence Can Inform Benefit Design

(R6) GLP-1 Agonists for Weight Management within the Commercially Insured Market: How Real-world Evidence Can Inform Benefit Design

Wednesday, October 16, 2024
4:15 PM – 5:30 PM PT
Location: 121
CPE
ACPE UAN:0233-0000-24-061-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
Use of GLP-1 agonists for weight management has substantially increased in recent years, creating considerable challenges for both employers and insurers offering coverage for these products. With over one-third of the U.S. adult population considered obese and multiple GLP-1 medications now approved by the U.S. Food and Drug Administration for weight management, these trends are expected to continue. This session will review published literature regarding real-world treatment characteristics of GLP-1 therapy for weight management and provide a detailed description of GLP-1 adherence, persistence, and clinical and economic outcomes from a cohort of commercially insured members with two years of follow-up after initiating a GLP-1 for weight management. Additionally, this session will discuss weight management strategies adopted by health plans and self-insured employers, as well as the use of this real-world evidence in benefit design recommendations.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Summarize current real-world evidence concerning persistence and adherence to GLP-1 therapies employed in the treatment of obesity, including off-label prescribing.
  2. Describe current real-world evidence concerning medical cost offsets associated with the treatment of obesity with GLP-1 drugs.
  3. Identify weight management strategies adopted by self-insured employers and health plans and the role of real-world evidence to inform weight management benefit design.